Clinical efficacy of TACE combined with sorafenib and ablation in the sequential treatment of large liver cancer and its influence on the time of postoperative disease progression

Abstract

Abstract: Objective To investigate the clinical efficacy of sequential treatment of large liver cancer with transarterial chemoembolization (TACE) combined with sorafenib and ablation, and its impact on postoperative disease-free survival time. Methods Clinical data of 86 patients with large liver cancer admitted to the No.988 Hospital of Joint Logistic Support Force from January 2020 to January 2022 were retrospectively collected. They were divided into a control group (n=40, treated with TACE combined with sorafenib) and a study group (n=46, treated with TACE combined with sorafenib and sequential ablation) according to different treatment methods. The efficacy, alpha-fetoprotein (AFP), health status, adverse reactions, and survival time were compared between two groups. Results The objective remission rate of the research group was 76.09%, significantly higher than the control group′s 50.00% (P<0.05); After treatment, the serum AFP level in the study group (124.29 ± 20.62) μg/L was lower than that in the control group (205.13 ± 32.59) μg/L. The KPS score in the study group after treatment (88.68 ± 9.03) was higher than that in the control group (79.38 ± 8.15), and the differences were statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions such as nausea, vomiting, diarrhea, fever, bone marrow suppression, and hand foot skin reactions between the two groups (P>0.05). The progression-free survival time and overall survival time of the study group were (16.01 ± 2.15) months and (19.37 ± 2.69) months, respectively, which were significantly longer than the control group′s (11.84 ± 1.62) months and (13.90 ± 2.04) months (P<0.05). Conclusion TACE combined with sorafenib and sequential ablation therapy has significant clinical efficacy in the treatment of large liver cancer, without significantly increasing the incidence of adverse reactions, and can effectively prolong the postoperative disease-free survival time of patients.

Key words: Primary liver cancer, Transhepatic arterial chemoembolization, Sorafenib, Microwave ablation

Wang Jianbin, Liang Dong. Clinical efficacy of TACE combined with sorafenib and ablation in the sequential treatment of large liver cancer and its influence on the time of postoperative disease progression[J]. Chinese Hepatolgy, 2026, 31(6): 822-825.

References

[1] Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022,77(6): 1598-1606.
[2] 吴小龙,邓婧,罗韬. 特瑞普利单抗联合仑伐替尼TACE治疗晚期肝癌的疗效及对肿瘤标志物预后的影响[J]. 河北医学, 2024, 30(10): 1745-1751.
[3] 章馨允, 郭洪生, 吴尘轩. 肝癌免疫治疗临床进展及展望[J]. 中国慢性病预防与控制, 2023, 31(2): 152-155.
[4] 梁昭君, 赵宝银, 张丽霞, 等. TACE联合索拉非尼治疗不可切除肝细胞癌疗效及安全性系统评价再评价[J]. 医学研究杂志, 2023, 52(11): 142-148.
[5] 符艳, 李肖, 张晓武, 等. 肝癌消融技术管理与多元化的肝癌消融治疗团队的构建[J]. 临床肝胆病杂志, 2021, 37(3): 497-500.
[6] Lencioni R, Llovet J M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1): 52-60.
[7] Friendlander A H, Ettinger R L. Karnofsky performance status scale[J]. Spec Care Dentist, 2009, 29(4): 147-148.
[8] 刘颖, 李涛, 李泽勇, 等. 多发和单发大肝癌中肝切除术和TACE治疗选择的研究进展[J]. 临床放射学杂志, 2024, 43(11): 2010-2015.
[9] 胡薪蕊, 吴熙, 殷玉琨,等. α-干扰素联合索拉非尼对肝癌细胞增殖的抑制作用及其对STAT3通路的影响[J]. 陕西医学杂志, 2024, 53(10): 1309-1313.
[10] 翟博. 肝癌局部消融术:体系建设与价值提升[J]. 肝胆胰外科杂志, 2023, 35(5): 257-262.
[11] 朱忠杰, 王喜功, 李雷,等. 经导管动脉内化疗栓塞术联合索拉非尼序贯微波消融和经导管动脉内化疗栓塞术联合索拉非尼治疗肿瘤直径>5 cm肝细胞癌的前瞻性研究[J]. 中华消化外科杂志, 2020, 19(2): 145-155.
[12] 陈俊伟, 赖丽莎, 罗骏阳,等. TACE联合射频消融及索拉非尼治疗巨块型肝细胞癌的回顾性研究[J]. 中华肝胆外科杂志, 2021, 27(1): 47-51.
[13] 丁海斌, 张欣, 李雅, 等. TACE序贯微波消融联合索拉非尼治疗大肝细胞癌患者临床疗效研究[J]. 实用肝脏病杂志, 2023, 26(1): 108-111.
[14] 罗铎, 欧志涛, 黄韫, 等. 原发性肝癌患者血清AFP、AFP-L3、PIVKA-Ⅱ水平及与病理特征和预后的关系分析[J]. 现代消化及介入诊疗, 2022, 27(2): 140-143.
[15] Zhou J, Ye D, Zhang S, et al. The impact of Karnofsky performance status on prognosis of patients with hepatocellular carcinoma in liver transplantation[J]. BMC Gastroenterol, 2024, 24(1): 85.